AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...
Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...
Pharmaceutical Technology on MSN3d
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancerThe US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...
The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...
A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback